SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.
Graf M, von Stuckrad SL, Uruha A, Klotsche J, Zorn-Pauly L, Unterwalder N, Buttgereit T, Krusche M, Meisel C, Burmester GR, Hiepe F, Biesen R, Kallinich T, Stenzel W, Schneider U, Rose T.
Graf M, et al. Among authors: krusche m.
RMD Open. 2022 Feb;8(1):e001934. doi: 10.1136/rmdopen-2021-001934.
RMD Open. 2022.
PMID: 35177553
Free PMC article.